Geron(GERN) Prnewswire·2025-04-12 14:53Core Viewpoint - Securities class action lawsuits have been filed against Geron Corporation for allegedly misleading investors regarding its revenue outlook and product performance during the specified Class Period from February 28, 2024, to February 25, 2025 [1]. Allegations of Misconduct - Defendants allegedly created a false impression of possessing reliable information about Geron's revenue outlook while downplaying risks from seasonality and macroeconomic factors [2]. - Reports regarding the launch success and growth potential of Geron's primary product, RYTELO, were claimed to be overly optimistic and did not reflect the reality of market conditions, competition, and monitoring burdens [2]. - RYTELO reportedly lacked market awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients and those outside academic settings [2]. - Statements made by the Defendants regarding the company's business and prospects were claimed to be materially false and misleading [2]. Lead Plaintiff Process - Investors in Geron have until May 12, 2025, to seek appointment as a lead plaintiff representative or may choose to remain absent class members [3]. - The lead plaintiff acts on behalf of all class members and is typically the investor or group of investors with the largest financial interest [3]. - The decision to serve as a lead plaintiff does not affect the ability to share in any recovery [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]. - The firm aims to protect investors and others from fraud and negligence by businesses [4].